Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Shipments of semiconductor process materials are expected to increase in ICT & Mobility Solutions. At Essential & Green Materials, business activities are progressing steadily against the risks factored into the previous forecast in consideration of the uncertain business environment and other factors. At Sumitomo Pharma, U.S. sales are performing strongly, driven mainly by Gemtesa. As a result, revenue, core operating profit, operating profit, and profit for the year attributable to owners of the parent are expected to exceed the previous forecast.
| Item | Details |
|---|---|
| Net Sales | ¥2,360,000 million → ¥2,490,000 million（5.5％） |
| Operating profit | ¥177,000 million → ¥215,000 million（21.5％） |
| Profit attributable to owners of the parent | ¥70,000 million → ¥90,000 million（28.6％） |
| Net income per share | 42.4 Yen/sen → 54.27 Yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 14 May 2026 |
| Previous-period results | Revenue: ¥2,328,515 million; core operating profit: ¥208,376 million; operating profit: ¥151,744 million; profit for the year attributable to owners of the parent: ¥60,947 million; basic earnings per share: ¥37.16 |
| Reason for the revision | Shipments of semiconductor process materials are expected to increase in ICT & Mobility Solutions. At Essential & Green Materials, business activities are progressing steadily against the risks factored into the previous forecast in consideration of the uncertain business environment and other factors. At Sumitomo Pharma, U.S. sales are performing strongly, driven mainly by Gemtesa. As a result, revenue, core operating profit, operating profit, and profit for the year attributable to owners of the parent are expected to exceed the previous forecast. |
| Dividend forecast revision | The year-end dividend forecast changed from ¥8.00 to ¥9.00, and the annual dividend forecast changed from ¥16.00 to ¥17.00. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The revision reflects the expected increase in shipments of semiconductor process materials in ICT & Mobility Solutions, steady progress in business activities at Essential & Green Materials against the risks factored in based on the uncertain business environment, and strong U.S. sales at Sumitomo Pharma, driven mainly by Gemtesa. The dividend was increased in line with the upward revision to the full-year consolidated earnings forecast.